Publikationer
2025
The DNA methylation landscape of primary triple-negative breast cancer Aine M, Nacer DF, Arbajian E, Veerla S, Karlsson A, Häkkinen J, Johansson HJ, Rosengren F, Vallon-Christersson J, Borg Å, Staaf J. Nat Commun. 2025 Mar 28;16(1):3041.
Genomic Characteristics Related to Histology-based Immune Features in Breast Cancer Cha YJ, O'Connell CE, Calhoun BC, Felsheim BM, Fernandez-Martinez A, Fan C, Brueffer C, Larsson C, Borg Å, Saal LH, Perou CM. Mod Pathol. 2025 Feb 14:100736. Online ahead of print.
Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance Albrecht J, Müller M, Hafstað V, Kaminska K, Vallon-Christersson J, Honeth G, Persson H. Mol Oncol. 2025 Jan;19(1):204-224. Epub 2024 Aug 6.
2024
Prediction of gene expression-based breast cancer proliferation scores from histopathology whole slide images using deep learning Ekholm A, Wang Y, Vallon-Christersson J, Boissin C, Rantalainen M. BMC Cancer. 2024 Dec 11;24(1):1510.
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Ullén S, Leandersson K, Bosch A, Staaf J, Killander F, Niméus E. Breast Cancer Res Treat. 2024 Dec 10. Online ahead of print.
The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? Vidal JM, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm DL, Hartman J, Acs B. EClinicalMedicine. 2024 Nov 15;78:102928. eCollection 2024 Dec.
Tumor purity estimated from bulk DNA methylation can be used for adjusting beta values of individual samples to better reflect tumor biology Sasiain I, Nacer DF, Aine M, Veerla S, Staaf J. NAR Genom Bioinform. 2024 Nov 4;6(4):lqae146. eCollection 2024 Sep.
Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression Godina C, Pollak MN, Jernström H. NPJ Precis Oncol. 2024 Oct 3;8(1):212.
Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells Roostee S, Ehinger D, Jönsson M, Phung B, Jönsson G, Sjödahl G, Staaf J, Aine M. Sci Rep. 2024 Sep 13;14(1):21417.
High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome Godina C, Khazaei S, Belting M, Vallon-Christersson J, Nodin B, Jirström K, Isaksson K, Bosch A, Jernström H. PLoS One. 2024 Jul 3;19(7):e0305222. eCollection 2024.
Kataegis in clinical and molecular subgroups of primary breast cancer Veerla S, Staaf J. NPJ Breast Cancer. 2024 Apr 24;10(1):32.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, Vidal Losada MJ, Seguí E, Angelats L, Garcia-Fructuoso I, Gómez-Bravo R, Lorman-Carbó N, Paré L, Marín-Aguilera M, Martínez-Sáez O, Adamo B, Sanfeliu E, Fratini B, Falato C, Chic N, Vivancos A, Villagrasa P, Staaf J, Parker JS, Perou CM, Prat A. EBioMedicine. 2024 Apr;102:105043. Epub 2024 Mar 5.
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling De Marchi T, Lai CF, Simmons GM, Goldsbrough I, Harrod A, Lam T, Buluwela L, Kjellström S, Brueffer C, Saal LH, Malmström J, Ali S, Niméus E. Sci Rep. 2024 Mar 22;14(1):6873.
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab Meng P, Dalal H, Chen Y, Brueffer C, Gladchuk S, Alcaide M, Ehinger A, Saal LH. NPJ Breast Cancer. 2024 Feb 19;10(1):14.
2023
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Bosch A, Staaf J, Killander F, Niméus E. Breast Cancer Res. 2023 Oct 10;25(1):123.
Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: A prospective multicenter cohort study Bengtsson Y, Demircan K, Vallon-Christersson J, Malmberg M, Saal LH, Rydén L, Borg Å, Schomburg L, Sandsveden M, Manjer J. Redox Biol. 2023 Jul;63:102728. Epub 2023 May 16.
Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study Nacer DF, Vallon-Christersson J, Nordborg N, Ehrencrona H, Kvist A, Borg Å, Staaf J.
Genome Med. 2023 Apr 14;15(1):25.
A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy Gulis K, Ellbrant J, Svensjö T, Skarping I, Vallon-Christersson J, Loman N, Bendahl PO, Rydén L. Eur J Surg Oncol. 2023 Jul;49(7):1189-1195. Epub 2023 Mar 28.
2022
Subtype and cell type specific expression of IncRNAs provide insight into breast cancer Bjørklund SS, Aure MR, Häkkinen J, Vallon-Christersson J, Kumar S, Evensen KB, Fleischer T, Tost J; OSBREAC; Sahlberg KK, Mathelier A, Bhanot G, Ganesan S, Tekpli X, Kristensen VN. Commun Biol. 2022 Aug 18;5(1):834.
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer Saghir H, Veerla S, Malmberg M, Rydén L, Ehinger A, Saal LH, Vallon-Christersson J, Borg Å, Hegardt C, Larsson C, Haidar A, Hedenfalk I, Loman N, Kimbung S.
Cancers (Basel). 2022 Aug 18;14(16):4000.
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J. NPJ Breast Cancer. 2022 Aug 16;8(1):94.
One-year recovery from breast cancer: Importance of tumor and treatment-related factors, resilience, and sociodemographic factors for health-related quality of life Velickovic K, Borrebaeck C, Bendahl PO, Hegardt C, Johnsson P, Richter C, Rydén L, Hallberg I. Front. Oncol. 2022 Aug 16, 12:891850.
Autoimmunity to selenoprotein P predicts breast cancer recurrence Demircan K, Sun Q, Bengtsson Y, Seemann P, Vallon-Christersson J, Malmberg M, Saal LH, Rydén L, Minich WB, Borg Å, Manjer J, Schomburg L. Redox Biol. 2022 Jul;53:102346. Epub 2022 May 25.
Clinical associations of ESR2 (estrogen receptor beta) expression across thousand of primary breast tumors Dalal H, Dahlgren M, Gladchuk S, Brueffer C, Gruvberger-Saal SK, Saal LH. Sci Rep. 2022 Mar 18;12(1):4696.
2021
Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, Malmberg M, Saal LH, Rydén L, Borg Å, Manjer J, Schomburg L. Redox Biol. 2021 Nov;47:102145. Epub 2021 Sep 21.
Association of mammographic features with molecular breast tumor profiles Sartor H, Zackrisson S, Hegardt C, Larsson C.
Cancer Treat Res Commun. 2021;28:100387. Pub 2021 May 9.
Psychological Resilience and Health-Related Quality of Life in 418 Swedish Women with Primary Breast Cancer: Results from a Prospective Longitudinal Study Mohlin Å, Bendahl PO, Hegardt C, Richter C, Rahm Hallberg I, Rydén L. Cancers (Basel). 2021 May 6;13(9):2233.
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer Dahlgren M, George AM, Brueffer C, Gladchuk S, Chen Y, Vallon-Christersson J, Hegardt C, Häkkinen J, Rydén L, Malmberg M, Larsson C, Gruvberger-Saal SK, Ehinger A, Loman N, Borg Å, Saal LH. JNCI Cancer Spectr. 2021 Apr 22;5(2):pkab028.
Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer Cieśla M, Ngoc PCT, Cordero E, Martinez ÁS, Morsing M, Muthukumar S, Beneventi G, Madej M, Munita R, Jönsson T, Lövgren K, Ebbesson A, Nodin B, Hedenfalk I, Jirström K, Vallon-Christersson J, Honeth G, Staaf J, Incarnato D, Pietras K, Bosch A, Bellodi C.
Mol Cell. 2021 Apr 1;81(7):1453-1468.e12. Epub 2021 Mar 3.
Molecular analyses of triple-negative breast cancer in the young and elderly Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J. Breast Cancer Res. 2021 Feb 10;23(1):20.
2020
Psychological Resilience and Health-Related Quality of Life in Swedish Women with Newly Diagnosed Breast Cancer Mohlin Å, Axelsson U, Bendahl PO, Borrebaeck C, Hegardt C, Johnsson P, Rahm Hallberg I, Rydén L. Cancer Manag Res. 2020 Nov 24;12:12041-12051.
The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Häkkinen J, George AM, Chen Y, Ehinger A, Larsson C, Loman N, Malmberg M, Rydén L, Borg Å, Saal LH. EMBO Mol Med. 2020 Oct 7;12(10):e12118. Epub 2020 Sep 14.
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J. Nat Commun. 2020 Jul 27;11(1):3747.
Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer Larsson C, Ehinger A, Winslow S, Leandersson K, Klintman M, Dahl L, Vallon-Christersson J, Häkkinen J, Hegardt C, Manjer J, Saal L, Rydén L, Malmberg M, Borg Å, Loman N. NPJ Breast Cancer. 2020 Jul 6;6:28.
Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer Persson H, Søkilde R, Häkkinen J, Vallon-Christersson J, Mitelman F, Borg Å, Höglund M, Rovira C. Int J Cancer. 2020 Jun 15;146(12):3343-3353.
2019
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S. Nat Med. 2019 Oct;25(10):1526-1533. Epub 2019 Sep 30.
Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series Vallon-Christersson J, Häkkinen J, Hegardt C, Saal LH, Larsson C, Ehinger A, Lindman H, Olofsson H, Sjöblom T, Wärnberg F, Ryden L, Loman N, Malmberg M, Borg Å, Staaf J. Sci Rep. 2019 Aug 21;9(1):12184.
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M. Breast Cancer Res Treat. 2019 Nov;178(2):459-467. Epub 2019 Aug 20.
Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population based cohort Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg A, Staaf J, Rydén L. Clin Cancer Res. 2019 Nov 1;25(21):6368-6381. Epub 2019 Jul 24.
Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment Förnvik D, Aaltonen KE, Chen Y, George AM, Brueffer C, Rigo R, Loman N, Saal LH, Rydén L. Breast Cancer Res Treat. 2019 Sep:177(2):447-455. Epub 2019 Jun 24.
Refinement of breast cancer molecular classification by miRNA expression profiles Søkilde R, Persson H, Ehinger A, Pirona AC, Fernö M, Hegardt C, Larsson C, Loman N, Malmberg M, Rydén L, Saal L, Borg Å, Vallon-Christerson J, Rovira C. BMC Genomics. 2019 Jun 17;20(1):503.
Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N. Genet Med. 2019 Jan;21(1):89-96. Epub 2018 Jun 6.
High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N. Breast Cancer Res Treat. 2019 Jan;173(2):313-318. Epub 2018 oct 11.
2018
A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study Axelsson U, Rydén L, Johnsson P, Edén P, Månsson J, Hallberg IR, Borrebaeck CAK. BMC Cancer. 2018 Aug 6;18(1):789.
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl PO, Manjer J, Malmberg M, Larsson C, Loman N, Rydén L, Borg Å, and Saal LH. JCO Precis Oncol. 2018 Mar 9;2:PO.17.00135. eCollection 2018.
Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, Lindman H, Ehinger A, Saal LH, Borg Å. Br J Surg. 2018 Jan;105(2):e158-e168.
2017
BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N.
Breast Cancer Res Treat. 2018 Feb;168(1):117-126. Epub 2017 Nov 21.
Frequent miRNA-convergent fusion gene events in breast cancer Persson H, Søkilde R, Häkkinen J, Pirona AC, Vallon-Christersson J, Kvist A, Mertens F, Borg Å, Mitelman F, Höglund M, Rovira C. Nat Commun. 2017 Oct 5;8(1):788.
2016
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH. Ann Oncol. 2016 Aug;27(8):1532-8. ePub 2016 May 18.
Implementation of an Open Source Software solution for Laboratory Information Management and automated RNAseq data analysis in a large-scale Cancer Genomics initiative using BASE with extension package Reggie Häkkinen J, Nordborg N, Månsson O, Vallon-Christersson J. bioRxiv Posted April 12, 2016. Preprint.
2015
The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicentre infrastructure towards implementation of breast cancer genomic analyses in the clinical routine Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å. Genome Med. 2015 Feb 2;7(1):20.
2014
Svenskt samarbete för genomiska analyser av bröstcancervävnad. Grund för framtidens individualiserade cancerbehandling Niklas Loman. Läkartidningen. 2014;111:CTEY.